Former Canon Slade School student shortlisted in excellence awards
A nursing student from Bolton was nominated as a finalist in three categories of the 2025 Student Nursing Times Awards – recognising excellence in nursing and midwifery education.
Eleanor Wilkinson, a student at The University of Plymouth was nominated as a finalist in three categories for this years' awards including Most Inspirational Student Nurse of the Year, Student Nurse of the Year, Student Nurse or Midwife of the Year – Clinical Research.
Eleanor, who was born and raised in Bolton - educated at Clevelands Preparatory School and Canon Slade CE School, where she took her GCSEs. She then attended Bolton College - completing her BTEC in Health and Social Care.
She worked in healthcare before embarking on her University course.
READ MORE:
Eleanor said: 'My student nursing journey has been full of challenges, growth, and incredible experiences, and I am beyond grateful for the support that has helped me get to this point.
'A huge thank you to the University, whose encouragement has shaped me into the student I am today. And to my mum, your unwavering belief in me has meant everything. I wouldn't be here without you.
'To everyone who has supported me along the way, thank you. This proves that anything is possible with enthusiasm, perseverance, and the right people by your side.
'For anyone on their own journey, never stop believing in yourself. You are capable of more than you know.'
The Student Nursing Times Awards were presented earlier this month at the JW Marriott Grosvenor House Hotel on Park Lane.
Over 900 attendees watched the spectacular event, across 25 categories and 100 judges.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. Related L'Oréal acquires Galderma stake and targets the injectables market The Body Shop goes into administration, with hundreds of UK jobs at risk This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
Two UK Cardiology Trials Struggle to Recruit Patients
MANCHESTER — Two ongoing cardiology trials in the UK are facing substantial recruitment challenges, researchers reported at the British Cardiovascular Society (BCS) Annual Conference 2025. The BRITISH study has enrolled fewer than one-third of its targeted 2504 patients over 2 years. Meanwhile, CRAAFT-HF has recruited just 22 of its 1200-patient goal since launching in December 2024. 'We are running behind schedule,' said Andrew Flett, a consultant cardiologist at University Hospital Southampton NHS Trust and principal investigator for BRITISH. 'We're running at about 50% of where we should be, and we're putting in every effort to try and improve that.' CRAAFT-HF's chief investigator Pier Lambiase, professor of cardiology at University College London, said that the trial's eligibility criteria were 'evolving' and being adjusted to boost recruitment. Entry Criteria Adjustments for CRAAFT-HF CRAAFT-HF is comparing surgical versus medical ablation of atrial fibrillation (AF) in people with heart failure and a reduced ejection fraction (EF) of 50%. The trial is still in its vanguard phase, with 14 centres open for an average of 4.5 months. The aim was to have at least 120-215 patients recruited across 10 sites within the first year. Professor Pier Lambiase Despite a large potential pool of patients with heart failure and AF seen in clinics, 'only about 5% are referred for ablation', Lambiase said. To improve recruitment, proposed changes include: Broadening the definition of AF to include paroxysmal and persistent types (up to 3 years' duration), confirmed by ECG, Holter monitoring, or cardiac implantable electronic devices (CIEDs). Relaxing inclusion thresholds for New York Heart Association (NYHA) class and LVEF thresholds. Removing NT-proBNP and medication optimisation criteria for trial eligibility. 'We've learned very quickly that this is threatening the trial,' Lambiase said. 'It's a lot of work to get the patient recruited, start optimal therapy, repeat the [echocardiogram], make sure they're still in the trial.' He estimated the revised criteria could have added 62 patients – tripling current enrolment. Lambiase remains optimistic, citing remote follow-up protocols and international collaboration plans with centres in Canada, Australia, Sweden, and Spain. Expanding the pool of associate principal investigators to include nurses and pharmacists may also help accelerate recruitment. The BRITISH Study The BRITISH study, active since 2023, is running at 46 of its planned 50 UK sites and actively recruiting. Ongoing since 2023, 46 out of the planned 50 sites are actively recruiting patients into the BRITISH study. It aims to determine whether scarring detected via cardiovascular magnetic resonance (CMR) is associated with reduced mortality in patients with nonischaemic cardiomyopathy and severe systolic heart failure (LVEF ≤35%) who receive implantable cardioverter defibrillators (ICDs). Andrew Flett Flett reported that of the 390 patients enrolled so far: Half were recruited within one year of diagnosis. Just under 20% were recruited within 6 months. Almost two-thirds had NYHA Class II heart failure. 38% had AF. Flett said this is 'the best-treated heart failure population in a heart failure trial that I'm aware of', noting high rates of evidence-based therapy: 93% on beta-blockers. 97% on antihypertensives. 92% on sodium-glucose cotransport 2 (SGLT2) inhibitors. 88% on mineralocorticoid receptor antagonists. The median age is 66 years. Most participants are White (93%) and male (80%). Addressing Gender Disparities in Trial Recruitment The under-representation of women — just 20% of the current cohort — is 'a major source of concern', Flett told Medscape News UK . The BCS and the British Heart Foundation Clinical Research Collaborative have previously highlighted the need to include more women in clinical trials. A consensus paper in the journal Heart , published at the start of the BCS annual conference, outlined strategies to improve female participation. However, Flett noted that nonischaemic cardiomyopathy is more common in men. 'We're going to recruit the patients that are there, and most of them are men,' he said. If we had 'the luxury of plenty of patients, we could obviously hold back on male recruitment', he added. Efforts are also underway to increase the number of female principal investigators (PIs). Currently, just 6 of the 46 site PIs are women. Recruitment could take another 2-3 years at the current pace. Plans are being considered to open additional sites in Australia and to remind UK centres of the importance of balanced gender recruitment. The BRITISH and CRAAFT-HF studies are funded by the British Heart Foundation. Flett and Lambiase had no conflicts of interest to disclose.
Yahoo
6 hours ago
- Yahoo
King Charles' Cancer Is Incurable, Bombshell Report Suggests
King Charles' will die 'with' but not 'of' cancer, a bombshell report claimed Saturday. The report essentially confirms long-standing rumors that the king's cancer is considered manageable but ultimately incurable, which is the case for many older individuals afflicted by the disease. Charles is 76. The report will be unwelcome in the palace, as it will reignite speculation that the king's health is in a delicate state, rumors that were rekindled when Prince Harry said in a recent BBC interview that he didn't know how long his father had left to live. Charles' aides have consistently briefed reporters that he is, broadly speaking, winning his battle against cancer, and the king himself recently said he was on 'the other side' of the health crisis. The king is back to essentially running a full diary after being diagnosed with cancer last year, albeit with some modifications. The report, by the respected royal writer and associate editor of the U.K. Daily Telegraph, Camilla Tominey, also claimed that Charles will never move into Buckingham Palace due to his health struggles. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she wrote. A spokesperson for the king declined to comment. Tominey, who was the first to break the news about Prince Harry and Meghan dating and also about the latter's row with Kate Middleton, added that planning for Charles' 80th birthday in 2028, while 'very tentative,' is going ahead. Tominey also claimed that Charles and Harry could be publicly reunited at the Invictus Games, in Birmingham in 2027, with palace aides quietly investigating whether the event could provide a suitable backdrop for a long-awaited reconciliation. It is understood officials hope any reconciliation would include Prince Archie and Princess Lilibet. The king last saw the children in 2022. Harry has said he can't bring his family safely to the U.K. and hinted some powerful palace figures want him dead. Intriguingly, Tominey suggests that a reconciliation might be considered because of the negative impact the narrative of estrangement is having on the king's reputation. She writes: 'There is an awareness that the impasse cannot continue forever, not least if it starts to reflect badly on the king.' Prince Harry said, in a bitter interview with the BBC following a comprehensive legal defeat on his security arrangements, that he does not know how long his cancer-hit father has left to live because the king won't speak to him. Harry also said he won't bring his family to the U.K., blamed his father for his security being reduced after leaving the royal family, and said he had 'forgiven' those family members who had hurt him. He added, 'Some members of my family will never forgive me for writing a book but I would love reconciliation with my family.' The prince continued, 'There is a lot of control and ability in my father's hands. Ultimately, this whole thing could be resolved through him.' Appearing emotional, Harry said, 'There's no point in continuing to fight anymore. As I said, life is precious. I don't know how much longer my father has. He won't speak to me because of this security stuff, but it would be nice to reconcile.'
